Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Expert's Video Prof. Zieroth Addressing hurdles in adopting CRM Management
05/05/2025 | Author: Boehringer Ingelheim
Document ID: PC-PH-106326